PHARMASPIRE - Volume 15, Issue 03, 2023 , July- September

Pages: 103-106

Date of Publication: 18-Dec-2023

Print Article   Download XML  Download PDF

De novo designing of novel drug-like inhibitors of aldose reductase

Author: Priyadarshi Gautam, Priya Bisht, Sant Kumar Verma

Category: P'Ceutical Chemistry

Abstract:

Aldose reductase (AR, ALR2) is a member of the aldo-keto reductase superfamily. It is the first and rate-limiting enzyme of the polyol pathway. AR plays an essential role in the development of diabetic complications. It is designated as the most legitimate target for managing diabetic complications. One of the key challenges to the successful development of target-specific AR inhibitors is target selectivity. In this research, target-specific drug-like ALR2 inhibitors have been designed using the de novo technique and are present for further synthesis and development.

Keywords: Aldose reductase, De novo designing, Diabetic complications, Polyol pathway

DOI: 10.56933/Pharmaspire.2023.15119

DOI URL: https://doi.org/10.56933/Pharmaspire.2023.15119

References:

1. Suryasa IW, Rodríguez-Gámez M, Koldoris T. Health and treatment of diabetes mellitus. Int J Health Sci 2021;5:1-5.

2. Thakur S, Gupta SK, Ali V, Singh P, Verma M. Aldose reductase: A cause and a potential target for the treatment of diabetic complications. Arch Pharm Res 2021;44:655-67.

3. Singh M, Kapoor A, Bhatnagar A. Physiological and pathological roles of aldose reductase. Metabolites 2021;11:655.

4. Quattrini L, La Motta C. Aldose reductase inhibitors: 2013-present. Expert Opin Ther Pat 2019;29:199-213.

5. Verma SK, Thareja S. Formylchromone derivatives as novel and selective PTP-1B inhibitors: A drug design aspect using molecular docking-based self-organizing molecular field analysis. Med Chem Res 2016;25:1433-67.

6. Verma SK, Thareja S. Molecular docking assisted 3D-QSAR study of benzylidene-2, 4-thiazolidinedione derivatives as PTP-1B inhibitors for the management of Type-2 diabetes mellitus. RSC Adv 2016;6:33857-67.

7. Douguet D, Munier-Lehmann H, Labesse G, Pochet S. LEA3D: A computer-aided ligand design for structurebased drug design. J Med Chem 2005;48:2457-68.

8. Douguet D. e-LEA3D: A computational-aided drug design web server. Nucleic Acids Res 2010;38:W615-21.

9. Banjare L, Verma SK, Jain AK, Thareja S. Structure guided molecular docking assisted alignment dependent 3DQSAR study on steroidal aromatase inhibitors (SAIs) as anti-breast cancer agents. Lett Drug Des Discov 2019;16:808-17.

10. Banjare L, Verma SK, Jain AK, Thareja S. Lead molecules as novel aromatase inhibitors: In silico de novo designing and binding affinity studies. Lett Drug Des Discov 2020;17:655-65.

11. Verma SK, Thareja S. Structure based comprehensive modelling, spatial fingerprints mapping and ADME screening of curcumin analogues as novel ALR2 inhibitors. PLoS One 2017;12:e0175318